Riquent yields strong data in lupus trials

10 June 2007

San Diego, USA-based drugmaker La Jolla Pharmaceutical says that data from trials of its developmental systemic lupus erythematosus treatment Riquent (abetimus sodium) indicates its efficacy.

The results, which were announced at the 8th International Congress on SLE in Shanghai, China, showed that treatment brought about a dose-dependant reduction in the level of disease antibodies, and was tolerated at doses of up to 2,400mg. In addition, the company reported that there were no serious adverse events in a study designed to assess the cardiovascular impact of the drug.

Deidre Gillespie, La Jolla's chief executive, said that Riquent had been designed to target the aberant aspects of the immune system responsible for the disease, while allowing the function of the normal immune response.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >

Today's issue

Company Spotlight

Evaxion

A TechBio company that specializes in developing personalized vaccines and immunotherapies through its advanced AI-Immunology™ platform. The company bridges artificial intelligence technology, bioinformatics, and drug development to bring novel immunotherapies to patients facing cancer and infectious diseases.